ResearcherAmsterdam University Medical CentersNo recent work listed
L. Bengt van Rijssen
Matched on ORCID iD 0000-0001-5918-1772; OpenAlex author ID A5020798051. Sources: OpenAlex.
Their work
- Papers
- 10 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 86
2016: 2 papers · 2017: 1 paper · 2018: 2 papers · 2019: 2 papers · 2020: 2 papers · 2021: none · 2022: 1 paper
Papers 10
- Added value of 3T MRI and the MRI-halo sign in assessing resectability of locally advanced pancreatic cancer following induction chemotherapy (IMAGE-MRI): pros… Co-author DOI 10.1007/s00423-022-02653-y↗
- Unsupervised class discovery in pancreatic ductal adenocarcinoma reveals cell-intrinsic mesenchymal features and high concordance between existing classificati… Co-author DOI 10.1038/s41598-019-56826-9↗
- Impact of nationwide enhanced implementation of best practices in pancreatic cancer care (PACAP-1): a multicenter stepped-wedge cluster randomized controlled t… Co-author DOI 10.1186/s13063-020-4180-z↗
- Added value of intra-operative ultrasound to determine the resectability of locally advanced pancreatic cancer following FOLFIRINOX chemotherapy (IMAGE): a pro… Co-author DOI 10.1016/j.hpb.2019.02.017↗
- Core Set of Patient-reported Outcomes in Pancreatic Cancer (COPRAC): An International Delphi Study Among Patients and Health Care Providers. Co-author DOI 10.1097/sla.0000000000002633↗
- Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease. First author DOI 10.1016/s1470-2045(18)30098-6↗
- ADAM12 is a circulating marker for stromal activation in pancreatic cancer and predicts response to chemotherapy. Co-author DOI 10.1038/s41389-018-0096-9↗
- Nationwide prospective audit of pancreatic surgery: design, accuracy, and outcomes of the Dutch Pancreatic Cancer Audit. Co-author DOI 10.1016/j.hpb.2017.06.010↗
- Recent Advances in Pancreatic Cancer Surgery of Relevance to the Practicing Pathologist. Co-author DOI 10.1016/j.path.2016.05.002↗
- Systematic Review of Resection Rates and Clinical Outcomes After FOLFIRINOX-Based Treatment in Patients with Locally Advanced Pancreatic Cancer. Co-author DOI 10.1245/s10434-016-5373-2↗
Closest collaborators
The 25 strongest of 86 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Marc G. Besselink · 9 shared papers, 2016–2022 · strength 0.62
- Paper Added value of 3T MRI and the MRI-halo sign in assessing resectability of locally advanced pancreatic cancer following … DOI 10.1007/s00423-022-02653-y↗
- Paper Unsupervised class discovery in pancreatic ductal adenocarcinoma reveals cell-intrinsic mesenchymal features and high c… DOI 10.1038/s41598-019-56826-9↗
- Paper Added value of intra-operative ultrasound to determine the resectability of locally advanced pancreatic cancer followin… DOI 10.1016/j.hpb.2019.02.017↗
- Hanneke W.M. van Laarhoven · 6 shared papers, 2018–2022 · strength 0.46
- Paper Added value of 3T MRI and the MRI-halo sign in assessing resectability of locally advanced pancreatic cancer following … DOI 10.1007/s00423-022-02653-y↗
- Paper Unsupervised class discovery in pancreatic ductal adenocarcinoma reveals cell-intrinsic mesenchymal features and high c… DOI 10.1038/s41598-019-56826-9↗
- Paper Added value of intra-operative ultrasound to determine the resectability of locally advanced pancreatic cancer followin… DOI 10.1016/j.hpb.2019.02.017↗
- Johanna W. Wilmink · 5 shared papers, 2016–2022 · strength 0.38
- Paper Added value of 3T MRI and the MRI-halo sign in assessing resectability of locally advanced pancreatic cancer following … DOI 10.1007/s00423-022-02653-y↗
- Paper Added value of intra-operative ultrasound to determine the resectability of locally advanced pancreatic cancer followin… DOI 10.1016/j.hpb.2019.02.017↗
- Paper Core Set of Patient-reported Outcomes in Pancreatic Cancer (COPRAC): An International Delphi Study Among Patients and H… DOI 10.1097/sla.0000000000002633↗
- Ignace H. J. T. de Hingh · 3 shared papers, 2017–2022 · strength 0.24
- Paper Added value of 3T MRI and the MRI-halo sign in assessing resectability of locally advanced pancreatic cancer following … DOI 10.1007/s00423-022-02653-y↗
- Paper Added value of intra-operative ultrasound to determine the resectability of locally advanced pancreatic cancer followin… DOI 10.1016/j.hpb.2019.02.017↗
- Paper Nationwide prospective audit of pancreatic surgery: design, accuracy, and outcomes of the Dutch Pancreatic Cancer Audit. DOI 10.1016/j.hpb.2017.06.010↗
- Izaak Quintus Molenaar · 4 shared papers, 2016–2019 · strength 0.24
- Paper Added value of intra-operative ultrasound to determine the resectability of locally advanced pancreatic cancer followin… DOI 10.1016/j.hpb.2019.02.017↗
- Paper Systematic Review of Resection Rates and Clinical Outcomes After FOLFIRINOX-Based Treatment in Patients with Locally Ad… DOI 10.1245/s10434-016-5373-2↗
- Paper Recent Advances in Pancreatic Cancer Surgery of Relevance to the Practicing Pathologist. DOI 10.1016/j.path.2016.05.002↗
- Krijn P. van Lienden · 2 shared papers, 2019–2022 · strength 0.20
- Paper Added value of 3T MRI and the MRI-halo sign in assessing resectability of locally advanced pancreatic cancer following … DOI 10.1007/s00423-022-02653-y↗
- Paper Added value of intra-operative ultrasound to determine the resectability of locally advanced pancreatic cancer followin… DOI 10.1016/j.hpb.2019.02.017↗
- Eran van Veldhuisen · 2 shared papers, 2019–2022 · strength 0.20
- Paper Added value of 3T MRI and the MRI-halo sign in assessing resectability of locally advanced pancreatic cancer following … DOI 10.1007/s00423-022-02653-y↗
- Paper Added value of intra-operative ultrasound to determine the resectability of locally advanced pancreatic cancer followin… DOI 10.1016/j.hpb.2019.02.017↗
- Marieke S. Walma · 3 shared papers, 2016–2019 · strength 0.19
- Paper Added value of intra-operative ultrasound to determine the resectability of locally advanced pancreatic cancer followin… DOI 10.1016/j.hpb.2019.02.017↗
- Paper Systematic Review of Resection Rates and Clinical Outcomes After FOLFIRINOX-Based Treatment in Patients with Locally Ad… DOI 10.1245/s10434-016-5373-2↗
- Paper Recent Advances in Pancreatic Cancer Surgery of Relevance to the Practicing Pathologist. DOI 10.1016/j.path.2016.05.002↗
- Hjalmar C. van Santvoort · 3 shared papers, 2016–2019 · strength 0.18
- Paper Added value of intra-operative ultrasound to determine the resectability of locally advanced pancreatic cancer followin… DOI 10.1016/j.hpb.2019.02.017↗
- Paper Systematic Review of Resection Rates and Clinical Outcomes After FOLFIRINOX-Based Treatment in Patients with Locally Ad… DOI 10.1245/s10434-016-5373-2↗
- Paper Nationwide prospective audit of pancreatic surgery: design, accuracy, and outcomes of the Dutch Pancreatic Cancer Audit. DOI 10.1016/j.hpb.2017.06.010↗
- Hanneke W. Wilmink · 2 shared papers, 2018–2020 · strength 0.14
- Paper Unsupervised class discovery in pancreatic ductal adenocarcinoma reveals cell-intrinsic mesenchymal features and high c… DOI 10.1038/s41598-019-56826-9↗
- Paper ADAM12 is a circulating marker for stromal activation in pancreatic cancer and predicts response to chemotherapy. DOI 10.1038/s41389-018-0096-9↗
- Veronique L. Veenstra · 2 shared papers, 2018–2020 · strength 0.14
- Paper Unsupervised class discovery in pancreatic ductal adenocarcinoma reveals cell-intrinsic mesenchymal features and high c… DOI 10.1038/s41598-019-56826-9↗
- Paper ADAM12 is a circulating marker for stromal activation in pancreatic cancer and predicts response to chemotherapy. DOI 10.1038/s41389-018-0096-9↗
- Frederike Dijk · 2 shared papers, 2018–2020 · strength 0.14
- Paper Unsupervised class discovery in pancreatic ductal adenocarcinoma reveals cell-intrinsic mesenchymal features and high c… DOI 10.1038/s41598-019-56826-9↗
- Paper ADAM12 is a circulating marker for stromal activation in pancreatic cancer and predicts response to chemotherapy. DOI 10.1038/s41389-018-0096-9↗
- Helene Damhofer · 2 shared papers, 2018–2020 · strength 0.14
- Paper Unsupervised class discovery in pancreatic ductal adenocarcinoma reveals cell-intrinsic mesenchymal features and high c… DOI 10.1038/s41598-019-56826-9↗
- Paper ADAM12 is a circulating marker for stromal activation in pancreatic cancer and predicts response to chemotherapy. DOI 10.1038/s41389-018-0096-9↗
- Maarten F. Bijlsma · 2 shared papers, 2018–2020 · strength 0.14
- Paper Unsupervised class discovery in pancreatic ductal adenocarcinoma reveals cell-intrinsic mesenchymal features and high c… DOI 10.1038/s41598-019-56826-9↗
- Paper ADAM12 is a circulating marker for stromal activation in pancreatic cancer and predicts response to chemotherapy. DOI 10.1038/s41389-018-0096-9↗
- Nadia Haj Mohammad · 2 shared papers, 2016–2019 · strength 0.13
- Paper Added value of intra-operative ultrasound to determine the resectability of locally advanced pancreatic cancer followin… DOI 10.1016/j.hpb.2019.02.017↗
- Paper Systematic Review of Resection Rates and Clinical Outcomes After FOLFIRINOX-Based Treatment in Patients with Locally Ad… DOI 10.1245/s10434-016-5373-2↗
- Johanna A.M.G. Tol · 2 shared papers, 2016–2020 · strength 0.13
- Joanne Verheij · 2 shared papers, 2016–2020 · strength 0.13
- Remy Klaassen · 1 shared paper, 2022 · strength 0.12
- Leonard W. F. Seelen · 1 shared paper, 2022 · strength 0.12
- Aart Johannes Nederveen · 1 shared paper, 2022 · strength 0.12
- Oliver J. Gurney‐Champion · 1 shared paper, 2022 · strength 0.12
- Thomas F. Stoop · 1 shared paper, 2022 · strength 0.12
- Hendrik A. Marsman · 1 shared paper, 2022 · strength 0.12
- Christopher Lee Wolfgang · 2 shared papers, 2017–2019 · strength 0.12
- Paper Core Set of Patient-reported Outcomes in Pancreatic Cancer (COPRAC): An International Delphi Study Among Patients and H… DOI 10.1097/sla.0000000000002633↗
- Paper Nationwide prospective audit of pancreatic surgery: design, accuracy, and outcomes of the Dutch Pancreatic Cancer Audit. DOI 10.1016/j.hpb.2017.06.010↗
- Steffi J. E. Rombouts · 2 shared papers, 2016 · strength 0.11
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.